Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).
Salubris Biotherapeutics has secured $32m in financing from Shenzhen Salubris Pharmaceuticals to advance its new complex biologics for oncology, cardiovascular and neurodegenerative diseases.
Helsinn Group has announced an update to its existing collaboration with BridgeBio Pharma to develop, produce and commercialise infigratinib for oncology indications in the US.
Epsilogen has raised $41.011m (£30.75m) in a Series B funding round led by new investor Novartis Venture Fund to further develop IgE-based antibody candidates for cancer treatment.
Biopharmaceutical firm Rondo Therapeutics has raised $67m in a Series A financing round to advance next-generation immuno-oncology platform to treat solid tumours.
ENA Respiratory has collaborated with not-for-profit organisation COPD Foundation for the development of INNA-051, a pan-antiviral nasal spray, for chronic lung diseases patients.
Genome engineering firm Synthego has raised $200m in Series E funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research.
Nurosene Health, through its subsidiary NetraMark, has collaborated with Cyclica for the development of new drugs to treat neurodegenerative diseases.
Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.
Healx, an AI-powered, technology company involved in the next generation of drug discovery, has secured an exclusive option to license rights to develop and commercialize gaboxadol from biopharmaceutical company Ovid Therapeutics.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.